Zifang Guo

Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial

Javier Cortés, David W. Cescon, Hope S. Rugo et al. · The Lancet · 2020 · 1.8K citations · Full text

Medicine, Oncology, Pharmacology +16

Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer

Javier Cortés, Hope S. Rugo, David W. Cescon et al. · New England Journal of Medicine · 2022 · 1.1K citations · Full text

Medicine, Oncology, Pharmacology +17

KEYNOTE-355: Randomized, double-blind, phase III study of pembrolizumab + chemotherapy versus placebo + chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer.

Javier Cortés, David W. Cescon, Hope S. Rugo et al. · Journal of Clinical Oncology · 2020 · 185 citations

Medicine, Oncology, Pharmacology +17

Human health risk assessment of groundwater arsenic contamination in Jinghui irrigation district, China

Yan Zhang, Xu Bin, Zifang Guo et al. · Journal of Environmental Management · 2019 · 130 citations

Pharmacy, Environmental Sciences, Toxicology +16

Fibrous dressing containing bioactive glass with combined chemotherapy and wound healing promotion for post-surgical treatment of melanoma

Caini Yuan, Daixing Zhang, Yujing Tang et al. · Biomaterials Advances · 2023 · 44 citations

Medicine, Oncology, Surgery +17